Scholar Rock Receives Fast Track Designation from the US FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock, a clinical-stage biopharmaceutical company, announced that the US FDA has granted Fast Track designation for apitegromab, a selective inhibitor of myostatin activation, for the treatment of patients with Spinal Muscular Atrophy.